Sivaraman Natarajan
Overview
Explore the profile of Sivaraman Natarajan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
703
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang J, Zheng Z, Jiao Y, Yu K, Bhatara S, Yang X, et al.
Nat Methods
. 2025 Mar;
PMID: 40074951
Spatial transcriptomics (ST) has advanced our understanding of tissue regionalization by enabling the visualization of gene expression within whole-tissue sections, but current approaches remain plagued by the challenge of achieving...
2.
Wang T, Liu L, Fang J, Jin H, Natarajan S, Sheppard H, et al.
Cancer Res
. 2024 Nov;
85(3):424-441.
PMID: 39531507
c-MYC is an important driver of high-risk neuroblastoma. A lack of c-MYC-driven genetically engineered mouse models (GEMM) has hampered the ability to better understand mechanisms of neuroblastoma oncogenesis and to...
3.
Chapple R, Liu X, Natarajan S, Alexander M, Kim Y, Patel A, et al.
Genome Biol
. 2024 Jun;
25(1):161.
PMID: 38898465
Background: Neuroblastoma is a common pediatric cancer, where preclinical studies suggest that a mesenchymal-like gene expression program contributes to chemotherapy resistance. However, clinical outcomes remain poor, implying we need a...
4.
Chapple R, Liu X, Natarajan S, Alexander M, Kim Y, Patel A, et al.
bioRxiv
. 2024 May;
PMID: 38712039
Neuroblastoma is a common pediatric cancer, where preclinical studies suggest that a mesenchymal-like gene expression program contributes to chemotherapy resistance. However, clinical outcomes remain poor, implying we need a better...
5.
Wang T, Liu L, Fang J, Jin H, Natarajan S, Sheppard H, et al.
bioRxiv
. 2024 Apr;
PMID: 38559042
The MYC proto-oncogenes (c-MYC, , ) are among the most deregulated oncogenic drivers in human malignancies including high-risk neuroblastoma, 50% of which are -amplified. Genetically engineered mouse models (GEMMs) based...
6.
Fang J, Singh S, Cheng C, Natarajan S, Sheppard H, Abu-Zaid A, et al.
Nat Commun
. 2023 Jul;
14(1):4003.
PMID: 37414763
A lack of relevant genetic models and cell lines hampers our understanding of hepatoblastoma pathogenesis and the development of new therapies for this neoplasm. Here, we report an improved MYC-driven...
7.
Hagiwara K, Natarajan S, Wang Z, Zubair H, Mulder H, Dong L, et al.
Cancer Discov
. 2023 Feb;
13(4):844-857.
PMID: 36751942
Significance: This first comprehensive CH analysis in long-term survivors of pediatric cancer presents the elevated prevalence and therapy exposures/diagnostic spectrum associated with CH. Due to the contrasting dynamics of clonal...
8.
Zubair A, Chapple R, Natarajan S, Wright W, Pan M, Lee H, et al.
Nucleic Acids Res
. 2022 May;
50(14):e80.
PMID: 35536287
Spatial transcriptomics technologies have recently emerged as a powerful tool for measuring spatially resolved gene expression directly in tissues sections, revealing cell types and their dysfunction in unprecedented detail. However,...
9.
Barsan V, Xia Y, Klein D, Gonzalez-Pena V, Youssef S, Inaba Y, et al.
Sci Adv
. 2022 Apr;
8(16):eabj1360.
PMID: 35442732
Treatment of acute lymphoblastic leukemia (ALL) necessitates continuous risk assessment of leukemic disease burden and infections that arise in the setting of immunosuppression. This study was performed to assess the...
10.
Pan M, Wright W, Chapple R, Zubair A, Sandhu M, Batchelder J, et al.
Nat Commun
. 2021 Nov;
12(1):6468.
PMID: 34753908
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20 years, with immunotherapies and targeted therapies having had minimal impact. Here, we identify the small molecule CX-5461...